UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

December 14, 2012

CHINA BCT PHARMACY GROUP, INC.

(Exact name of registrant as specified in its charter)

Delaware		033-145620		20- 8067060
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

No. 102, Chengzhan Road

Liuzhou City, Guangxi Province, P.R.C. 545007

(Address of principal executive offices, including zip code)

(011) 86-(772) 363 8318

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

£ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

£ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

£ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

£ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 4.01 Change in Registrant’s Certifying Accountant

Effective December 1, 2012, the Glendale, California office of PKF, Certified Public Accountants, A Professional Corporation (“PKF”), our independent registered public accounting firm, moved their practice to another independent registered accounting firm, Hutchinson and Bloodgood, LLP, also located in Glendale, California. As with PKF, Hutchinson and Bloodgood LLP is a member firm of the PKF International Limited network of legally independent firms. As a result of the move, on December 14, 2012, the Company’s Audit Committee approved the termination of PKF and the engagement of Hutchinson and Bloodgood LLP as the Company’s independent registered public accounting firm.

In connection with the audits of the Company’s financial statements for the fiscal years ended December 31, 2010 and 2011 and the subsequent interim period through November 14, 2012, (i) PKF’s report on the financial statements for such periods did not contain any adverse opinion or disclaimer or opinion, nor were such reports qualified or modified as to uncertainty, audit scope, or accounting principles, (ii) there were no disagreements with PKF on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreements, if not resolved to PKF’s satisfaction, would have caused PKF to make reference in connection with its opinion to the subject matter of the disagreement, and (iii) there were no “reportable events,” as that term is described in Item 304(a)(1)(v) of Regulation S-K.

Attached as Exhibit 16.1 is a copy of PKF’s letter addressed to the SEC relating to the statements made by the Company in this Current Report on Form 8-K.

During the Company’s two most recent fiscal years and in the subsequent interim period prior to November 14, 2012, the Company did not consult with Hutchinson and Bloodgood LLP regarding (i) the application of accounting principles to a specific completed or contemplated transaction, or the type of audit opinion that might be rendered on the Company’s consolidated financial statements and no written or oral advice was provided by Hutchinson and Bloodgood LLP that was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue or (ii) any matter that was either the subject of a disagreement or event, as set forth in Item 304(a)(1)(iv) or Item 304(a)(1)(v) of Regulation S-K.

Item 9.01. Financial Statements and Exhibits.

(d) The following exhibit is filed with this report.

Exhibit Number		Description
16.1		Letter of PKF to the SEC dated December 17, 2012

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	China BCT Pharmacy Group, Inc.

Date: December 18, 2011	/s/ Tang Huitian
	Tang Huitian
	Chief Executive Officer

China BCT Pharmacy Group, Inc. 8-K